Table 1:
Demographics and clinical characteristics of participants randomized to ibudilast (IBUD) versus placebo (PLA) conditions
| IBUD (N=64) | PLA (N=61) | P value | |
|---|---|---|---|
| Age, mean years (SD) | 38.8 (8.89) | 40.1 (11) | 0.50 |
| Gender, % (N) | |||
| Men | 76.6% (49) | 70.5% (43) | 0.60 |
| Women | 23.4% (15) | 29.5% (18) | |
| Race, % (N) | |||
| African American | 10.9% (7) | 11.5% (7) | 0.80 |
| American Indian/Alaska Native | 3.12% (2) | 3.28% (2) | |
| Asian | 6.25% (4) | 3.28% (2) | |
| Unknown/Not Reported | 32.8% (21) | 31.1% (19) | |
| More than One Race | 1.56% (1) | 0% (0) | |
| Native Hawaiian/Other Pacific Islander | 0% (0) | 1.64% (1) | |
| White | 45.3% (29) | 49.2% (30) | |
| Ethnicity, % (N) | |||
| Hispanic or Latino | 46.9% (30) | 49.2% (30) | 0.90 |
| Not Hispanic or Latino | 53.1% (34) | 50.8% (31) | |
| Substance use in past 30 days, mean days (SD) | |||
| Methamphetamine | 22.3 (8.97) | 22.1 (9.37) | 0.90 |
| Cannabis | 10.17 (13.1) | 6.11 (10.7) | 0.06 |
| Alcohol | 3.11 (6.38) | 5.59 (9.43) | 0.09 |
| Cigarette smoker, % (N) | |||
| Smoker | 68.8% (44) | 55.7% (34) | 0.20 |
| Non-smoker | 31.2% (20) | 44.3% (27) | |
| HIV serostatus | |||
| HIV positive | 21.9% (14) | 21.3% (13) | 1.00 |
| HIV negative | 78.1% (50) | 78.7% (48) |